[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632127":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":56,"studyPopulation":35,"armGroups":57,"interventions":70,"overallOfficials":35,"centralContacts":78,"locations":88,"responsibleParty":246,"collaborators":35,"id":250,"slug":35,"hasResults":251,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":251,"sex":257,"minAge":258,"maxAge":35,"enrollmentInfo":259,"targetDuration":35,"studyType":262,"phases":263,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":91,"whyStopped":35,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":283},{"fullName":5,"class":6},"Capital Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients with a modified Rankin Scale (mRS) score of 0-3 at 90 days.","The mRS ranges from 0 to 6, with higher scores indicating worse outcomes.","90 days",[14,16,20,24,26,28,30,33],{"measure":15,"description":11,"timeFrame":12},"mRS score distribution at 90 days;",{"measure":17,"description":18,"timeFrame":19},"Early neurological improvement at 24 hours","Defined as a reduction in NIHSS score of at least 8 points from baseline or a score of 0 to 2","24 hours",{"measure":21,"description":22,"timeFrame":23},"NIHSS score at 7 days or at early discharge","The NIHSS ranges from 0 to 42, with higher scores indicating worse outcomes","7 days",{"measure":25,"description":11,"timeFrame":12},"Proportion of patients with mRS score 0-1 at 90 days",{"measure":27,"description":11,"timeFrame":12},"Proportion of patients with mRS score 0-2 at 90 days",{"measure":29,"description":11,"timeFrame":12},"Proportion of patients with mRS score 0-4 at 90 days",{"measure":31,"description":32,"timeFrame":12},"EQ-5D-5L at 90 days","The EQ-5D-5L comprises the same five dimensions: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN \u002F DISCOMFORT and ANXIETY \u002F DEPRESSION, each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to\u002Fextreme problems.",{"measure":34,"description":35,"timeFrame":12},"Proportion of Barthel Index (BI) 95-100 at 90 days",null,[37,39,41,43],{"measure":38,"description":35,"timeFrame":19},"Incidence of symptomatic intracranial hemorrhage within 24 hours",{"measure":40,"description":35,"timeFrame":19},"Incidence of any intracranial hemorrhage within 24 hours",{"measure":42,"description":35,"timeFrame":23},"Proportion of patients with pneumonia at 7 days or at early discharge",{"measure":44,"description":35,"timeFrame":12},"Mortality at 90 days",{"allocation":46,"interventionModel":47,"interventionModelDescription":35,"primaryPurpose":48,"observationalModel":35,"timePerspective":35,"maskingInfo":49},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":50,"maskingDescription":35,"whoMasked":51},"QUADRUPLE",[52,53,54,55],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","This is an investigator-initiated, prospective, multicenter phase III clinical trial. This trial aims to investigate whether tocilizumab could further improve prognosis for patients with acute posterior circulation large-vessel occlusion stroke receiving endovascular therapy.",[58,64],{"label":59,"type":60,"description":61,"interventionNames":62},"Tocilizumab","EXPERIMENTAL","Endovascular treatment combined with a 240mg tocilizumab injection once",[63],"Drug: Tocilizumab",{"label":65,"type":66,"description":67,"interventionNames":68},"Placebo","PLACEBO_COMPARATOR","Endovascular treatment combined with placebo",[69],"Drug: Placebo",[71,75],{"type":72,"name":59,"description":73,"armGroupLabels":74,"otherNames":35},"DRUG","240 mg of tocilizumab injection will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour.",[59],{"type":72,"name":65,"description":76,"armGroupLabels":77,"otherNames":35},"An equivalent volume of placebo will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour.",[65],[79,84],{"name":80,"role":81,"phone":82,"phoneExt":35,"email":83},"Xunming Ji","CONTACT","01083198962","jixm@ccmu.edu.cn",{"name":85,"role":81,"phone":86,"phoneExt":35,"email":87},"Chuanjie Wu","01083199439","wuchuanjie@ccmu.edu.cn",[89,106,119,131,143,155,168,180,188,200,213,225,237],{"facility":90,"status":91,"city":92,"state":93,"zip":94,"country":95,"countryCode":96,"cosmosGeoPoint":97,"geoPoint":102,"contacts":103},"Suzhou Municipal Hospital","RECRUITING","Suzhou","Anhui","234000","China","CN",{"type":98,"coordinates":99},"Point",[100,101],116.97889,33.63611,{"lat":101,"lon":100},[104],{"name":105,"role":81,"phone":35,"phoneExt":35,"email":35},"Zhengfei Ma",{"facility":107,"status":91,"city":108,"state":109,"zip":110,"country":95,"countryCode":96,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Anyang People's Hospital","Anyang","Henan","455000",{"type":98,"coordinates":112},[113,114],114.38278,36.096,{"lat":114,"lon":113},[117],{"name":118,"role":81,"phone":35,"phoneExt":35,"email":35},"Jiangang Zhang",{"facility":120,"status":91,"city":121,"state":109,"zip":122,"country":95,"countryCode":96,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Nanyang Central Hospital","Nanyang","473000",{"type":98,"coordinates":124},[125,126],112.54659,33.00524,{"lat":126,"lon":125},[129],{"name":130,"role":81,"phone":35,"phoneExt":35,"email":35},"Yifeng Liu",{"facility":132,"status":91,"city":133,"state":109,"zip":134,"country":95,"countryCode":96,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"The First Affiliated Hospital of Henan Medical University","Xinxiang","453000",{"type":98,"coordinates":136},[137,138],113.80151,35.19033,{"lat":138,"lon":137},[141],{"name":142,"role":81,"phone":35,"phoneExt":35,"email":35},"Hongkai Cui",{"facility":144,"status":91,"city":145,"state":109,"zip":146,"country":95,"countryCode":96,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"People's Hospital of Xihua","Zhoukou","466600",{"type":98,"coordinates":148},[149,150],114.63333,33.63333,{"lat":150,"lon":149},[153],{"name":154,"role":81,"phone":35,"phoneExt":35,"email":35},"Chaoqun Li",{"facility":156,"status":91,"city":157,"state":158,"zip":159,"country":95,"countryCode":96,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"People's Hospital of Linyi","Linyi","Shandong","276000",{"type":98,"coordinates":161},[162,163],118.34278,35.06306,{"lat":163,"lon":162},[166],{"name":167,"role":81,"phone":35,"phoneExt":35,"email":35},"Hao Wang",{"facility":169,"status":91,"city":170,"state":158,"zip":171,"country":95,"countryCode":96,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Zibo Central Hospital","Zibo","255000",{"type":98,"coordinates":173},[174,175],118.06333,36.79056,{"lat":175,"lon":174},[178],{"name":179,"role":81,"phone":35,"phoneExt":35,"email":35},"Liangjie Wang",{"facility":181,"status":91,"city":182,"state":183,"zip":184,"country":95,"countryCode":96,"cosmosGeoPoint":35,"geoPoint":35,"contacts":185},"Xianyang First People's Hospital","Xianyang","Shanxi","712000",[186],{"name":187,"role":81,"phone":35,"phoneExt":35,"email":35},"Xingyun Yuan",{"facility":189,"status":91,"city":190,"state":183,"zip":191,"country":95,"countryCode":96,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Yuncheng Central Hospital","Yuncheng","044000",{"type":98,"coordinates":193},[194,195],110.99278,35.02306,{"lat":195,"lon":194},[198],{"name":199,"role":81,"phone":35,"phoneExt":35,"email":35},"Bin Wang",{"facility":201,"status":91,"city":202,"state":203,"zip":204,"country":95,"countryCode":96,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Lishui Central Hospital","Lishui","Zhejiang","323000",{"type":98,"coordinates":206},[207,208],119.91029,28.46042,{"lat":208,"lon":207},[211],{"name":212,"role":81,"phone":35,"phoneExt":35,"email":35},"Xiao Peng",{"facility":214,"status":91,"city":215,"state":203,"zip":216,"country":95,"countryCode":96,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Taizhou enze Hospital","Taizhou","318000",{"type":98,"coordinates":218},[219,220],121.43312,28.66266,{"lat":220,"lon":219},[223],{"name":224,"role":81,"phone":35,"phoneExt":35,"email":35},"Shaoqing Jiang",{"facility":226,"status":91,"city":227,"state":203,"zip":228,"country":95,"countryCode":96,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"People's Hospital of Yueqing","Yueqing","325600",{"type":98,"coordinates":230},[231,232],120.96121,28.11941,{"lat":232,"lon":231},[235],{"name":236,"role":81,"phone":35,"phoneExt":35,"email":35},"Saizhen Wu",{"facility":238,"status":91,"city":239,"state":35,"zip":240,"country":95,"countryCode":96,"cosmosGeoPoint":241,"geoPoint":245,"contacts":35},"Capital Medical Univercity Xuanwu Hospital","Beijing","100053",{"type":98,"coordinates":242},[243,244],116.39723,39.9075,{"lat":244,"lon":243},{"type":247,"investigatorFullName":248,"investigatorTitle":249,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","Professor of Neurology, Capital Medical University Xuanwu Hospital","100632127",false,"NCT07509645","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3","IRIS-3","Inclusion Criteria:\n\n1. Age 18 years or older, of either sex;\n2. Acute ischemic stroke caused by occlusion of the basilar artery;\n3. Decide to undergo emergency endovascular treatment;\n4. Time from stroke onset to groin puncture within 24 hours;\n5. National Institutes of Health Stroke Scale (NIHSS) ≥ 10;\n6. Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6;\n7. Signed informed consent from the patients or the legally authorized representatives.\n\nExclusion Criteria:\n\n1. Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;\n2. Pre-stroke modified Rankin scale (mRS) score \\>1;\n3. Known allergy to tocilizumab or excipients;\n4. Known allergy to iodinated contrast agents;\n5. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;\n6. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases;\n7. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite blood pressure control;\n8. Neutrophils \\\u003C 2 × 10\\^9 \u002FL;\n9. Platelets \\\u003C 100 × 10\\^9 \u002FL;\n10. Blood glucose \\\u003C2.8 mmol\u002FL (50 mg\u002FdL) or \\>22.2 mmol\u002FL (400 mg\u002FdL);\n11. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\>2 times the upper limit of normal;\n12. Known recent or current serum creatinine \\>2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin;\n13. Pregnant, lactating, or planning pregnancy within 90 days;\n14. Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia;\n15. Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days;\n16. Presence of autoimmune diseases or use of immunosuppressive drugs;\n17. Systemic infectious diseases;\n18. Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study;\n19. Any circumstance that, as assessed by the investigators, might result in harm to the patients if study therapy is initiated;\n20. Other conditions that the investigator considers might affect compliance or preclude participation in this study.","ALL","18 Years",{"count":260,"type":261},348,"ESTIMATED","INTERVENTIONAL",[264],"PHASE3","This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.",[267],"Ischemic Stroke",[269,270,271,272,273],"large vessel occlusion","endovascular treatment","posterior circulation","interleukin-6 inhibitor","neuroprotection","2026-04-29",{"date":276,"type":277},"2026-05-05","ACTUAL",{"date":279,"type":277},"2026-04-22",{"date":281,"type":261},"2027-04-20",{"name":5,"class":6},13]